Editorial & Advertiser disclosure

Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Finance

Roche targets double-digit market share in weight loss, aims to catch up with Novo Nordisk, Handelsblatt reports

Published by Global Banking & Finance Review

Posted on March 3, 2026

1 min read

· Last updated: April 2, 2026

Add as preferred source on Google

Roche targets double-digit market share in weight loss, aims to catch up with Novo Nordisk, Handelsblatt reports

Finance Markets Pharmaceuticals

Global Banking & Finance Awards 2026 — Call for Entries

BERLIN, March 3 (Reuters) - Swiss pharmaceutical company Roche is aiming for a double-digit market share in the weight loss market and wants to close the gap on its Danish rival Novo Nordisk, its CEO

Roche Targets Top Three in Double-Digit Weight Loss Market Share Ambitions

Roche's Strategic Goals in the Weight Loss Market

CEO Outlines Market Share Ambitions

BERLIN, March 3 (Reuters) - Swiss pharmaceutical company Roche is aiming for a double-digit market share in the weight loss market and wants to close the gap on its Danish rival Novo Nordisk, its CEO told Germany's Handelsblatt business daily.

Top Three Market Position Targeted

"We expect to be among the top three in the market at the very least," Roche Chief Executive Thomas Schinecker said in an interview with the newspaper published on Tuesday.

Reporting and Editorial Credits

(Writing by Linda Pasquini; Editing by Christopher Cushing)

Key Takeaways

Roche is targeting a double‑digit share of the global weight‑loss market, hoping to position itself at least in the top three—challenging leaders Novo Nordisk and Eli Lilly.
The weight‑loss drug market is rapidly expanding—from about $72 billion to $139 billion by 2030—with GLP‑1 therapies dominating over 90 % market share held by Novo Nordisk and Lilly. Roche's push reflects growing competition and opportunity in the space (nypost.com).
Roche’s plan builds on its major biotech partnership with Zealand Pharma, investing over $5 billion to co‑develop injectable obesity treatments like petrelintide and CT‑388 combinations to rival products from Novo and Lilly (investopedia.com).

References

Frequently Asked Questions

What market share is Roche aiming for in the weight loss sector?

Roche is targeting a double-digit share in the weight loss market.

Who is Roche's main competitor in the weight loss market?

Roche is aiming to close the gap with Danish rival Novo Nordisk.

What is Roche's goal for its market position in weight loss treatments?

Roche expects to be among the top three companies in the weight loss market.

Who announced Roche's ambitions in the weight loss market?

Roche CEO Thomas Schinecker announced these ambitions in an interview.

More from Finance

Explore more articles in the Finance category

Fertiliser plant in Russia's Vologda region damaged in Ukrainian drone attack, governor says

Close Brothers will not take legal action against Britain's car finance redress scheme, Sky News reports

Germany's far-right AfD rises to record 28%, INSA poll shows

German government suspects Russia of Signal attack targeting politicians, sources say

Romania finds parts of second drone after overnight Russian attack on Ukraine

China condemns EU's inclusion of Chinese entities in sanctions package against Russia

Russian parliament speaker in North Korea to mark Pyongyang's troop deployment in Ukraine war

Macron reaffirms efforts to reopen Strait of Hormuz, as TotalEnergies warns of energy shortages

France's Macron says EU mutual assistance clause is unambiguous

US to let Venezuela pay Maduro's lawyer in drug trafficking case

Italy votes down equal parental leave while fathers redefine their role online

German auto industry faces even tougher competition as China economy slows

View All Finance Posts

Roche targets double-digit market share in weight loss, aims to catch up with Novo Nordisk, Handelsblatt reports

Roche Targets Top Three in Double-Digit Weight Loss Market Share Ambitions